[Salicylamide-- a potential pain-remedy alternative in the analgesic asthma syndrome]

Z Gesamte Inn Med. 1979 Dec 1;34(23):698-701.
[Article in German]

Abstract

Central pathogenetic mechanism of the analgesics-asthma-syndrome is very probably an analgesics-conditioned inhibition of the prostaglandin-biosynthesis (cyclooxygenase). Salicylamide, an analgesic without effect on the prostaglandin synthesis was in the oral exposition test of 18 patients with proved analgesics-asthma-syndrome in the dosage of 500 mg subjectively and objectively tolerated without reaction. Body-plethysmographically in consistent thoracic gas volume a slight decrease of the airways resistance could be registered. At the model of the isolated trachea of guinea-pigs salicylamide, in contrast to indomethacin and phenazone (prostaglandin-synthesis inhibitory substances) did not lead to an increase of the acetylcholine-induced spasm. Salcylamide can, after a tolerability test, be recommended as alternative analgesic in the analgesics-asthma-syndrome in a dosage of 500 mg.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Analgesics* / therapeutic use
  • Animals
  • Antipyrine / pharmacology
  • Asthma / chemically induced*
  • Bronchial Spasm / chemically induced
  • Cyclooxygenase Inhibitors
  • Female
  • Guinea Pigs
  • Humans
  • Indomethacin / pharmacology
  • Male
  • Prostaglandin Antagonists
  • Salicylamides / pharmacology*
  • Salicylamides / therapeutic use
  • Trachea / drug effects

Substances

  • Analgesics
  • Cyclooxygenase Inhibitors
  • Prostaglandin Antagonists
  • Salicylamides
  • Antipyrine
  • Indomethacin